🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Open questions in the 1L treatment of HER2+ metastatic breast cancer — by Otto Metzger. #IBC #IBCE25 #GotoPER #MJHLifeSciences

🤔How can we ⬆️ access to innovation for ALL 🌎🌍🌏patients with #breastcancer Breast International Group 📝 npj Journals Free access link 👉rdcu.be/ev9HQ Successes of the past ✅ Pitfalls of the present ✅ Solutions for the future eg @Path4Young✅ 🙏to co-✍️& funders 💶

Viktiga synpunkter från min kollega Matilda Liljedahl! Enkät: Negativa följder när läkare tar över administrativa arbetsuppgifter lakartidningen.se/aktuellt/nyhet… via @

When I say … informed consent - McGrath - Medical Education - Wiley Online Library …epublications.onlinelibrary.wiley.com/doi/10.1111/me…

How peer coaching can contribute to doctors’ development as clinical supervisors: an interview study | BMC Medical Education | Full Text bmcmededuc.biomedcentral.com/articles/10.11…

Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. ja.ma/3GSEPOQ

Yes. Writing is not a second thing that happens after thinking. The act of writing is an act of thinking. Writing *is* thinking. Students, academics, and anyone else who outsources their writing to LLMs will find their screens full of words and their minds emptied of thought.

🩺 How can we improve communication between doctors and patients? 💪 How can you become your own health advocate? 🔗abcglobalalliance.org/honestly-spoken

Gene expression profiling in breast cancer brain mets Among matched pairs, 42% lost ER, 55% lost PR, 45% gained HER2 & 42% acquired a basal-like phenotype. BM showed ↓luminal markers & ↑immune genes, revealing molecular divergence from the primaries esmoopen.com/article/S2059-…

Follow-up results from the POSITIVE Trial regarding breastfeeding after hormone receptor-positive #BreastCancer show no differences in breast cancer related events in women who breastfed compared with those who did not. 👉pubmed.ncbi.nlm.nih.gov/40632989/ Fedro Peccatori MD, PhD Ann Partridge MD, MPH

Dela linkedin.com/pulse/challeng… @emir This summer’s article. Read it! ”Questions before methods" - research questions should determine methodology, not preset hierarchies

🚨 VIKTORIA-1 in HR+/HER2– PIK3CA WT ABC (post-CDK4/6) 💥 Gedatolisib + fulvestrant ± palbo improved mPFS: ▪️Triplet: 9.3 mo vs 2.0 (HR 0.24) ▪️Doublet: 7.4 mo vs 2.0 (HR 0.33) But fulvestrant-only arms in other trials had higher mPFS—control underperformed? 🤔 HR’s on fire,

It warms my 🫀(and frankly brings a tear to my 👁️) to see Anne Loeser’s legacy live on (and grow!!): first citation in this Journal of Clinical Oncology publication. Patient-led PCDI The Right Dose is small, but mighty. ascopubs.org/doi/10.1200/JC…

Now out in The Lancet the results of the randomized trial ASTER 70s The addition of adjuvant CT to HT had no significant survival benefit in women aged >=70 years with a GGI high-risk ER+ HER2-neg early BC, and had more toxicity 👵🏻🛑 OncoAlert thelancet.com/journals/lance…

flamman.se/sjukvarden-har…

dn.se/sverige/amanda…

T-DXd Retreatment After ILD (Pooled analysis – 9 trials, 2145 pts) 🔹️23% of pts with G1 ILD were retreated 🔹️ILD recurrence in 33% (all G1–2, no G5) 🔹️20% discontinued due to ILD2 🔹️75% of steroid-treated pts recovered 💥 Retreatment appears feasible with proper

Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial - PMC pmc.ncbi.nlm.nih.gov/articles/PMC12…

Meet the experts shaping the Breast Track at #ESSO44! Led by Isabel Rubio, this track will include: - Minimally invasive techniques - AI & personalized strategies - Multidisciplinary management of breast cancer 🔗 Full programme & early reg: esso44.org OncoAlert

DB-06 approval summary, by U.S. FDA published in Journal of Clinical Oncology. Several interesting considerations, including the unexpected PFS HR 1.02 in the 11% of pts enrolled in North America. The FDA acknowledges the need to understand the activity of T-DXd in HER2-null. ascopubs.org/doi/10.1200/JC…